RHAMM/HMMR-, PRAME-, and G250/CA9-derived peptides for T-cell responses
Peptide . | Sequence . | Specific immune responses of patients with AML in CR no. (%) . | Specific immune responses of patients with refractory AML no. cases examined (%) . |
|---|---|---|---|
| RHAMM/HMMR-R3 | ILSLELMKL | 8/17 (47) | 0/10 (0) |
| PRAME-P1 | VLDGLDVLL | 1/7 (14) | ND |
| PRAME-P3 | ALYVDSLFFL | 7/10 (70) | 4/10 (40) |
| C250/CA9-G1 | HLSTAFARV | 1/8 (13) | ND |
| G250/CA9-G2 | QLLLSLLLL | 6/10 (60) | 0/10 (0) |
Peptide . | Sequence . | Specific immune responses of patients with AML in CR no. (%) . | Specific immune responses of patients with refractory AML no. cases examined (%) . |
|---|---|---|---|
| RHAMM/HMMR-R3 | ILSLELMKL | 8/17 (47) | 0/10 (0) |
| PRAME-P1 | VLDGLDVLL | 1/7 (14) | ND |
| PRAME-P3 | ALYVDSLFFL | 7/10 (70) | 4/10 (40) |
| C250/CA9-G1 | HLSTAFARV | 1/8 (13) | ND |
| G250/CA9-G2 | QLLLSLLLL | 6/10 (60) | 0/10 (0) |
ND indicates not done.